We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

183 hedge funds and large institutions have $980M invested in AbCellera Biologics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 63 increasing their positions, 55 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

504% more call options, than puts

Call options by funds: $13.3M | Put options by funds: $2.2M

15% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 55

0.47% more ownership

Funds ownership: 44.73% → 45.19% (+0.47%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

10% less funds holding

Funds holding: 203 → 183 (-20)

24% less capital invested

Capital invested by funds: $1.3B → $980M (-$316M)

45% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 40

Holders
183
Holders Change
-20
Holders Change %
-9.85%
% of All Funds
2.92%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
22
Increased
63
Reduced
55
Closed
40
Calls
$13.3M
Puts
$2.2M
Net Calls
+$11.1M
Net Calls Change
-$189K

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$8.44M
2
Millennium Management
Millennium Management
New York
+$7.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$6.26M
4
HF
HRT Financial
New York
+$5.05M
5
CS
Credit Suisse
Switzerland
+$4.61M

Top Sellers

1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$8.89M
2
TC
TwinBeech Capital
New York
-$5.31M
3
N
Nuveen
North Carolina
-$3.58M
4
Man Group
Man Group
United Kingdom
-$3.09M
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$150M +$1.21M +132,916 +0.7%
BlackRock
2
BlackRock
New York
$103M -$1.43M -157,707 -1%
VOYA Investment Management
3
VOYA Investment Management
Georgia
$81.7M -$1.61M -176,837 -2%
BBA
4
Baker Bros. Advisors
New York
$78.8M – – –
Capital World Investors
5
Capital World Investors
California
$70.3M – – –
CS
6
Credit Suisse
Switzerland
$34.7M +$4.61M +507,665 +12%
O
7
OrbiMed
New York
$31.5M – – –
HMC
8
Harvard Management Company
Massachusetts
$31M – – –
FFVM
9
Founders Fund VII Management
California
$28.5M – – –
State Street
10
State Street
Massachusetts
$25.6M +$1.09M +120,418 +4%
Lazard Asset Management
11
Lazard Asset Management
New York
$24.5M +$3.06M +336,987 +12%
Federated Hermes
12
Federated Hermes
Pennsylvania
$21.9M +$3.47M +381,937 +15%
Renaissance Technologies
13
Renaissance Technologies
New York
$21.2M +$6.26M +689,100 +32%
CC
14
Casdin Capital
New York
$19M +$2.27M +250,000 +11%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$16.4M +$981K +108,035 +5%
GCAC
16
Guardian Capital Advisors (Canada)
Ontario, Canada
$13M – – –
Northern Trust
17
Northern Trust
Illinois
$12.7M -$508K -55,960 -3%
Norges Bank
18
Norges Bank
Norway
$11.9M +$8.44M +928,962 +144%
Citadel Advisors
19
Citadel Advisors
Florida
$11.1M +$80.7K +8,884 +0.6%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$11.1M -$8.89M -979,008 -40%
American Century Companies
21
American Century Companies
Missouri
$9.59M +$39.4K +4,335 +0.3%
Millennium Management
22
Millennium Management
New York
$9.1M +$7.08M +779,150 +182%
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$8.68M +$334K +36,747 +3%
NHAS
24
Novo Holdings A/S
Denmark
$8.5M – – –
Vanguard Group
25
Vanguard Group
Pennsylvania
$7.46M +$114K +12,597 +1%
1
2 3 4 5

ABCL Hedge Fund Activity: Q1 2023 in Review

183 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2023, worth a combined $980M — down 24% from $1.3B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of ABCL and 22 opened new positions — a net loss of 18 holders — while 55 trimmed existing stakes and 63 added.

The largest buyer was Norges Bank, adding an estimated $8.44M. The largest seller was D.E. Shaw & Co, cutting an estimated $8.89M.

  • 183 institutional investors held AbCellera Biologics (ABCL) as of Q1 2023, down from 203 in Q4 2022.
  • Funds reported $980M of AbCellera Biologics stock for Q1 2023, down 24% quarter-over-quarter.
  • 22 funds opened new AbCellera Biologics positions in Q1 2023 and 40 closed out, a net change of -18 holders.
  • The largest AbCellera Biologics buyer in Q1 2023 was Norges Bank, an estimated $8.44M added.
  • The largest AbCellera Biologics seller in Q1 2023 was D.E. Shaw & Co, an estimated $8.89M sold.

Based on aggregated 13F filings for Q1 2023.